Neurotoxicity, consistent with immune effector cell-associated neurotoxicity syndrome (ICANS), was observed in all patients at both dose levels tested (107 CAR-T-EGFR-IL13Rα2 cells, n = 3 and 2.5 × 107 CAR-T-EGFR-IL13Rα2 cells, n = 3), and managed using high-dose dexamethasone and anakinra (IL-1R agonist). This evidence concerns the gene IL13RA2 and toxic encephalopathy.